An experimental COVID-19 antiviral has been shown to cut the risk of hospital admission in half and appears to work across variants. Despite its promising attributes, it’s unlikely to reach the U.S. market anytime soon because of regulatory challenges and a lack of funding, The New York Times reported Feb. 8.
Read the full post on Becker's Hospital Review - Healthcare News
